|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
|
31423712 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, clinical studies indicate that circulating, mature GDF15 is an independent biomarker for heart failure.
|
30104250 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
As well, GDF-15 was found a prognostic biomarker of heart failure and acute coronary syndrome.
|
21718220 |
2011 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism.
|
28846098 |
2017 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NRG-1/ErbB2 gene polymorphisms were not associated with heart failure risk or prognosis.
|
26844763 |
2016 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discrimination of subjects with and without HF was slightly higher for GDF-15 (area under the ROC curve [AUC]:0.79 [95%CI:0.75-0.83]) compared to NT-proBNP (AUC:0.77 [95% CI:0.72-0.82]).
|
27838133 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, seven groups of biomarkers associated to myocardial stretch (mid-regional proatrial natriuretic peptide, MR-proANP), myocyte injury (high-sensitive troponins, hs-cTn; heart-type fatty acid-binding protein, H-FABP; glutathione transferase P1, GSTP1), matrix remodeling (galectin-3; soluble isoform of suppression of tumorigenicity 2, sST2), inflammation (growth differentiation factor-15, GDF-15), renal dysfunction (neutrophil gelatinase-associated lipocalin, NGAL; kidney injury molecule-1, KIM-1), neurohumoral activation (adrenomedullin, MR-proADM; copeptin), and oxidative stress (ceruloplasmin; myeloperoxidase, MPO; 8-hydroxy-2'-deoxyguanosine, 8-OHdG; thioredoxin 1, Trx1) in HF will be overviewed.
|
28212715 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we evaluated whether GDF-15 was associated with CV death or heart failure (HF) across the spectrum of risk in non-ST-segment elevation (NSTE)-ACS.
|
30710475 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition to regulating body weight, MIC-1/GDF15 may be used to predict mortality and/or disease course in cancer, cardiovascular disease (CVD), chronic renal and heart failure, as well as pulmonary embolism.
|
20854422 |
2010 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Little is known about GDF-15 as a biomarker in patients with heart failure.
|
20855664 |
2010 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
NT-proBNP and MR-proANP were lower in obese vs. non-obese HF individuals (p = 0.013 and p = 0.01, respectively), whereas GDF-15 was similar and MR-proADM was higher in obese vs. non-obese HF individuals.
|
28004184 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is a promising biomarker for prediction of HF and death due to CHD in the general population, which may provide prognostic information to already established clinical biomarkers.
|
29771963 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We assessed GDF-15 levels in 910 patients enrolled in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial, a randomized clinical trial of exercise training in patients with HFrEF.Median follow-up was 30 months.
|
28958347 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to analyse the association between high-level growth-differentiation factor-15 (GDF-15) and mortality, recurrent MI and heart failure compared to low-level GDF-15 in patients with acute coronary syndrome (ACS).
|
31029521 |
2019 |
|
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08-1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05-1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05-1.28, P < 0.001).
|
30204280 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although, in general, effects of NRG-1 in heart failure are compensatory and beneficial, translation into therapies remains unaccomplished both because of the complexity of the underlying pathways and because of the challenges in the development of therapeutics (proteins, peptides, small molecules, and RNA-based therapies) for tyrosine kinase receptors.
|
31607147 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher NT-proBNP, hsTnT, and GDF-15 were also associated with a greater risk of HF with reduced EF; while higher NT-proBNP GDF-15 and sST2 were associated with HF with preserved EF.
|
31645163 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the setting of ACS, GDF-15 is associated with long-term all-cause death, MACE and heart failure and provides incremental prognostic value beyond traditional risks factor.
|
31369736 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 reflects chronic disease burden and acute perturbations in HF and responds to improvements in hemodynamic status.
|
28062617 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In pooled analysis of both cohorts, higher levels of nine proteins were associated with incident heart failure after adjustment for established risk factors: growth differentiation factor 15 (GDF-15), T-cell immunoglobulin and mucin domain 1 (TIM-1), tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), spondin-1 (SPON1), matrix metalloproteinase-12 (MMP-12), follistatin (FS), urokinase-type plasminogen activator surface receptor (U-PAR), osteoprotegerin (OPG), and suppression of tumorigenicity 2 (ST2).
|
28967680 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease.
|
30935637 |
2019 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pooled results showed that overexpression of GDF-15 was associated with poor survival in heart failure patients (log unit GDF-15: hazard ratio = 1.86, 95% CI = 1.37-2.52).
|
27454651 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hazard ratio for the composite end point for the highest compared to the lowest quartile of GDF-15 was 1.8 (95% CI, 1.5-2.2); for CV death, 2.63 (1.9-3.6); for sudden death, 3.06 (1.9-4.8); for heart failure (HF) death, 4.3 (1.3-14); for cancer death, 2.5 (1.3-4.7); for hospitalization for HF, 5.8 (3.2-10); for MI 1.4 (95% CI, 1.1-1.9); and for stroke, 1.8 (95% CI, 1.1-2.8).
|
27811204 |
2017 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death.
|
30427997 |
2018 |